0001225208-13-001248.txt : 20130109
0001225208-13-001248.hdr.sgml : 20130109
20130109174433
ACCESSION NUMBER: 0001225208-13-001248
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20130101
FILED AS OF DATE: 20130109
DATE AS OF CHANGE: 20130109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ballinger Kevin J.
CENTRAL INDEX KEY: 0001566080
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 13521235
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: ONE BOSTON SCIENTIFIC PLACE
CITY: NATICK
STATE: MA
ZIP: 01760
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BOSTON SCIENTIFIC PL
CITY: NATICK
STATE: MA
ZIP: 01760-1537
BUSINESS PHONE: 508-650-8000
MAIL ADDRESS:
STREET 1: ONE BOSTON SCIENTIFIC PL
CITY: NATICK
STATE: MA
ZIP: 01760-1537
3
1
doc3.xml
X0206
3
2013-01-01
0
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001566080
Ballinger Kevin J.
ONE BOSTON SCIENTIFIC PLACE
NATICK
MA
01760-1537
1
SVP & Pres, Interven Cardio
Common Stock
91825.0000
D
Deferred Stock Units
2013-02-12
Common Stock
5913.0000
D
Deferred Stock Units
2015-02-16
Common Stock
34413.0000
D
Deferred Stock Units
2014-02-24
Common Stock
6291.0000
D
Deferred Stock Units
2017-02-27
Common Stock
15924.0000
D
Deferred Stock Units
2016-02-28
Common Stock
22346.0000
D
Deferred Stock Units
2013-10-28
Common Stock
2594.0000
D
Stock Option (Right to Buy)
6.2800
2022-02-27
Common Stock
37497.0000
D
Stock Option (Right to Buy)
6.3100
2020-10-25
Common Stock
100000.0000
D
Stock Option (Right to Buy)
7.1600
2021-02-28
Common Stock
62112.0000
D
Stock Option (Right to Buy)
7.4100
2020-02-16
Common Stock
23077.0000
D
Stock Option (Right to Buy)
7.7100
2018-10-28
Common Stock
36630.0000
D
Stock Option (Right to Buy)
8.3000
2019-02-24
Common Stock
35000.0000
D
Stock Option (Right to Buy)
15.9100
2016-10-31
Common Stock
17100.0000
D
Stock Option (Right to Buy)
21.7800
2013-02-25
Common Stock
8000.0000
D
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 12, 2009, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 12, 2008, which will continue to vest in one remaining installment on the anniversary of the date of grant.
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 16, 2010, which will continue to vest in three equal annual installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 24, 2009, which will continue to vest in two equal annual installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 28, 2011, which will continue to vest in four equal annual installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 28, 2009, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on October 28, 2008, which will continue to vest in one remaining installment on the anniversary of the date of grant.
Grant to the reporting person of an option to purchase 37,497 shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 100,000 shares of common stock vesting in four equal annual installments beginning on October 25, 2011, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 62,112 shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 23,077 shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 36,630 shares of common stock on October 28, 2008. This option is fully vested.
Grant to the reporting person of an option to purchase 35,000 shares of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 17,100 shares of common stock on October 31, 2006. This option is fully vested.
Grant to the reporting person of an option to purchase 8,000 shares of common stock on February 25, 2003. This option is fully vested.
poaballinger.txt
/s/ Conor Kilroy, Attorney-in-Fact
2013-01-09
EX-99
2
poaballinger.txt
POWER OF ATTORNEY
Know all by these present that the undersigned hereby constitutes and appoints
each of Timothy A. Pratt, Vance R. Brown, Theresa R. Boni, Todd D. Hammond and
Conor Kilroy signing singly, the undersigned's true and lawful attorney-in-fact
to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an executive officer and/or director of Boston Scientific
Corporation (the "Company"), Forms 3, 4 and 5, and amendments thereto, in
accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended, and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5 and file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority;
(3) execute for and on behalf of the undersigned, in the undersigned's
capacity as an executive officer and/or director of the Company, Forms 144 in
accordance with Rule 144 of the Securities Act of 1933, as amended, and the
rules and regulations thereunder; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the
Securities Act of 1933, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with
respect to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 30th day of December, 2012.
/s/ Kevin J. Ballinger
Kevin J. Ballinger